Pharmacokinetics of high-dose @entity70779 in XXXX with @entity1577 .

@entity1 @entity70779 @entity17286 @entity10817 @entity1577 @entity11929
The pharmacokinetics of high-dose @entity70779 was studied in 18 @entity1 with @entity1577 . Nine male and nine female @entity1 with a mean age of 14.7 years (range 3 to 29 years) participated in the study. They received @entity17286 450 mg/kg/day (as the @entity11929 ) in six divided doses. During a steady-state dosing interval, a dose of @entity17286 was coadministered with a 10-mg/kg dose of @entity10817 as a 30-minute infusion. Serum concentrations of @entity17286 and @entity10817 were determined by high-pressure liquid chromatography assay. The data were analyzed using model-independent methods. The mean elimination rate constant for @entity17286 was 0.64 +/- 0.22 hr-1 and the mean serum half-life was 1.22 +/- 0.39 hr. Total clearance of @entity17286 , calculated by noncompartmental analysis, was 77.2 +/- 26.4 mL/min/sq m. Glomerular filtration rate, as estimated by measuring @entity10817 clearance, was 79.6 +/- 21.9 mL/min/sq m. The total clearance of @entity17286 correlated with @entity10817 clearance. @entity1 with @entity1577 appear to eliminate @entity17286 more rapidly than healthy individuals. This rapid elimination warrants the use of high doses to maintain high serum concentrations.
